Previous 10 | Next 10 |
BURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, t...
BURLINGTON, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, t...
Summary After two CRLs, FUROSCIX has finally received FDA approval. This treatment could be a game-changer in the treatment of heart failure, allowing certain patients to avoid costly hospitalizations altogether and simply self-administer treatment at home. The stock has been ...
Summary SCPH's lead drug candidate FUROSCIX was approved on October 10th by the FDA. To help distribute the drug, SCPH secured a $100 million loan. SCPH closed down almost 20% on the back of these two events. Introduction I give a hold rating to scPharmaceutica...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Connect world / Shutterstock.com Applied DNA (NASDAQ: APDN ) stock is rocketing higher on Monday after the company announced a massive order for its LinearDNA product . LinearDNA is an enzymatic manuf...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips There were not just one, but two press releases from scPharmaceuticals (NASDAQ: SCPH ) this morning. Apparently, the U.S. Food and Drug Administration (FDA) approved Furoscix. Furthermore, scPharmaceuticals has agreed...
FUROSCIX demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide Commercial launch planned in Q1 2023 BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical co...
The U.S. Food and Drug Administration (FDA) approved scPharmaceuticals ( NASDAQ: SCPH ) Furoscix's to treat congestion due to fluid overload in adults with New York Heart Association Class 2/3 chronic heart failure. Furoscix, a proprietary formulation of furosemid...
BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, t...
FUROSCIX demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide Commercial launch planned in Q1 2023 BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical co...
News, Short Squeeze, Breakout and More Instantly...
scPharmaceuticals Inc. Company Name:
SCPH Stock Symbol:
NASDAQ Market:
scPharmaceuticals Inc. Website:
BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today an...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 208.7% to $0.1698 on volume of 325,435,783 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 76.7% to $0.5039 on volume of 314,353,673 shares Greenwave Technology Solutions Inc. (GWAV) ros...
Generated 1Q 2024 net FUROSCIX ® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents o f $58.4 million Company to host investor conference call and web...